Humanity first Study of CLB-3000 and preclinical data demonstration at AASLD 2023 to treat chronic hepatitis B infection
Concord, Massachusetts, October 12, 2023–(BUSINESS WIRE)–ClearB Therapeutics, Inc., now a clinical-stage biotechnology company developing therapies to promote functional cure for patients with chronic hepatitis B (CHB) infection, announces first Patients are already being evaluated in a Phase 1b clinical study of the therapeutic vaccine CLB-3000 (ACTRN1263000841673). Satisfactory review of safety data in this patient supports open enrollment for the remainder of the cohort.
CLB-3000 is a bivalent subunit therapeutic vaccine composed of CLB-405 and CLB-505 proteins and adjuvanted with AlHydrogel®. CLB-405 and CLB-505 were designed to overrepresent clearance spectrum epitopes identified from functionally cured patients. The Phase 1b study was an open-label, dose-escalation design enrolling up to 36 patients with chronic hepatitis B in up to 3 cohorts. The study targets the safety, tolerability and antiviral activity of CLB-3000. Results from the two dose-escalation cohorts are expected in February 2024.
“We are very excited to advance our therapeutic vaccine candidate, CLB-3000, into human trials in patients with chronic hepatitis B. We look forward to sharing new clinical data with the hepatitis B community,” said Aileen Rubio. , Ph.D., CEO of the company. “CHB infection remains a significant global health care problem that requires safe and effective treatments. We believe that boosting a patient’s own immune system with ClearB’s therapeutic vaccine, CLB-3000, could become an important component of evolving combination treatment regimens part.”
Additionally, ClearB Therapeutics announced the acceptance of an abstract containing new preclinical data on a humanized monoclonal antibody as a serum therapy for the treatment of CHB to be presented at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting. Boston, MA, November 10-14, 2023.
Dr. Rubio added, “We are also excited to continue to present new preclinical data on another novel immune serum therapy at the upcoming AASLD Liver Meeting.” For more information about the 2023 AASLD Liver Meeting, visit Liver Meeting | AASLD Liver Meeting.
Abstract number: Chapter 1541
Abstract title: Humanized monoclonal antibody 4G2 exhibits antiviral activity in a mouse model of persistent hepatitis B virus (HBV) infection
Speaker’s name: Aditi Deshpande
About hepatitis B
The World Health Organization defines hepatitis B as “a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection, leaving people at risk of cirrhosis and liver disease. High risk of death.” cancer. ” About 2 billion people are infected with HBV and about 250 million people are infected with CHB. Viral hepatitis is the 7thth Liver cancer ranks third among causes of death in humansRD The most common cause of cancer-related death worldwide.
About ClearB Therapy
ClearB Therapeutics was co-founded in 2017 with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop immune-based therapies designed to drive functional cure for hepatitis B infection. This work is based on proprietary insights from studies of resolution of rare-event infections in patients with chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231012033794/en/
Contact information
ClearB Therapeutics
pr@clearbtherapeutics.com